Arrowhead Research | ARWR - Interest Expense On Debt


Arrowhead Research reported $22.5M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 343M 39M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
TG Therapeutics USD 7.67M 1.13M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 4.7M 2.65M Mar/2026